Form 4: Richard Ian Griffiths Reports Increased Stake in Silence Therapeutics plc

Director Richard Ian Griffiths reports acquiring additional American Depositary Shares (ADS) of Silence Therapeutics plc, increasing his beneficial ownership.

Summary

• Richard Ian Griffiths, a director of Silence Therapeutics plc, filed a Form 4 detailing changes in his beneficial ownership of the company's securities.
• Griffiths acquired American Depositary Shares (ADS) through a series of transactions between April 10, 2025, and April 15, 2025.
• The purchases were made at prices ranging from $2.14 to $2.78 per ADS.
• Each ADS is immediately convertible into three ordinary shares.
• Following these transactions, Griffiths' direct ownership increased to 10,061,299 ordinary shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The director's increased stake could be seen as a vote of confidence, but it's a routine filing and doesn't contain enough information to strongly influence sentiment.

Positives

• The director's increased investment could be interpreted as a positive signal about the company's prospects.

Industry Context

Form 4 filings are standard practice and provide transparency into the trading activities of company insiders, which can be closely watched by investors for signals about the company's health and prospects.

Stakeholder Impact

• Shareholders may view the director's increased stake as a positive sign.

Key Dates

Keywords

Silence Therapeutics, Richard Ian Griffiths, ADS, Beneficial Ownership, Form 4, Securities, Director, Transactions